REFERENCES
- Georgopapadakou NH, Walsh TJ. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother 1996; 40 (2): 279–291.
- Ghannoum MA. Future of antimycotic therapy. Dermatol Ther 1997; 3: 104–111.
- Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid for-mulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27 (3): 603–618.
- Lozano-Chiu M, Paetznick VL, Ghannoum MA, Rex JH. Detection of resistance to amphotericin B among Cryptococ-cus neoformans clinical isolates: performances of three different media assessed by using E-Test and National Committee for Clinical Laboratory Standards M27-A methodologies. J Clin Microbiol 1998; 36 (10): 2817–2822.
- Johnson EM, Ojwang JO, Szekely A, Wallace TL, Warnock DW. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother 1998; 42 (6): 1412–1416.
- Oakley KL, Moore CB, Denning DW. Comparison of In vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother 1999; 43 (5): 1264–1266.
- Tollemar J, Ringden O. Lipid formulations of ampho-tericin B: less toxicity but at what economic cost? Drug Safety 1995; 13 (4): 207–218.